Akebia Therapeutics, Inc. AKBA
0.90
(0.02)
(2.17%)
as of 25 Sep
- Market cap
- $254.7M
- P/E
- 0.0×
Follow AKBA
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| ROE | (109.38%) | (78.96%) | 64.49% | 361.06% |
+8 more TTM periods Free account |
| ROA | (8.53%) | (6.10%) | (1.79%) | (5.57%) | |
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% | |
| Return on Tangible Assets | (42.26%) | (29.07%) | (5.86%) | (12.58%) | |
| Average Days of Receivables | 89.15 | 98.22 | 72.68 | 107.39 | |
| Free Cash Flow per Share | 0.15 | 0.22 | 0.26 | 0.12 | |
| Free Cash Flow | 40.26 | 60.04 | 67.87 | 32.35 | |
| Capital Expenditures | (1.29) | (0.33) | (0.12) | (0.05) | |
| Piotroski F-Score | 4.00 | 6.00 | 7.00 | 7.00 | |
| Other line items | |||||
| Cash ROIC | 18.06% | 25.27% | 25.59% | 12.67% | |
| Accounts Receivable Turnover | 3.47 | 3.75 | 5.80 | 4.57 | |
| Accounts Payable Turnover | 4.26 | 4.19 | 2.17 | 4.01 | |
| Inventory Turnover | 3.00 | 2.70 | 2.48 | 2.42 | |
| Average Days of Payables | 77.05 | 69.37 | 195.95 | 77.85 | |
| Days of Inventory on Hand | 106.46 | 107.50 | 144.38 | 143.89 | |
| Tax Rate | 0.07 | 0.00 | (0.38) | (0.21) | |
| Research and Development Expense of Revenue | 32.16% | 29.01% | 26.40% | 21.10% | |
| Selling, General and Administrative Expense of Revenue | 51.94% | 48.27% | 45.50% | 48.46% | |
| Share Based Compensation of Revenue | 6.08% | 5.49% | 4.78% | 4.35% | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | (1.40) | (2.94) | (12.72) | (2.04) | |
| Depreciation/Fixed assets | 1.03 | 1.34 | 1.04 | 6.99 | |
| Capex/Depreciation | (0.83) | (0.26) | (0.09) | 0.00 | |
| Revenue per Share | 0.81 | 0.87 | 0.92 | 0.85 | |
| Operating CF per Share | 0.15 | 0.23 | 0.26 | 0.12 | |
| Capex per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capex to Sales | 0.01 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin | (13.54%) | (8.83%) | (2.26%) | (7.07%) |
Columns are period end dates